表紙
市場調査レポート

Biolab Sanus Farmaceutica Ltda. :製品パイプライン分析

Biolab Sanus Farmaceutica Ltda. - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 321957
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Biolab Sanus Farmaceutica Ltda. :製品パイプライン分析 Biolab Sanus Farmaceutica Ltda. - Product Pipeline Review - 2014
出版日: 2014年12月31日 ページ情報: 英文 24 Pages
概要

Biolab Sanus Farmaceutica Ltda. は処方薬を開発・製造・商品化し、輸出している製薬会社です。同社製品の対象となる疾患の範囲は、心臓系、皮膚科、内分泌系、婦人科系 、小児科、消化器系、整形外科、リウマチで、サプリメントも製造しています。

当レポートでは、Biolab Sanus Farmaceutica Ltda.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Biolab Sanus Farmaceutica Ltda.の基本情報

Biolab Sanus Farmaceutica Ltda.の概要

  • 主要情報
  • 企業情報

Biolab Sanus Farmaceutica Ltda.:R&Dの概要

  • 主な治療範囲

Biolab Sanus Farmaceutica Ltda.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Biolab Sanus Farmaceutica Ltda.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Biolab Sanus Farmaceutica Ltda.:薬剤プロファイル

  • BL-123
  • BL-125
  • PB-5109
  • BL-122
  • BL-214
  • BL-249

Biolab Sanus Farmaceutica Ltda.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Biolab Sanus Farmaceutica Ltda.:本社と子会社の所在地

付録

図表

目次
Product Code: GMDHC06777CDB

Summary

Global Markets Direct's, 'Biolab Sanus Farmaceutica Ltda. - Product Pipeline Review - 2014', provides an overview of the Biolab Sanus Farmaceutica Ltda.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biolab Sanus Farmaceutica Ltda.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Biolab Sanus Farmaceutica Ltda. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biolab Sanus Farmaceutica Ltda.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Biolab Sanus Farmaceutica Ltda.'s pipeline products

Reasons to buy

  • Evaluate Biolab Sanus Farmaceutica Ltda.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biolab Sanus Farmaceutica Ltda. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biolab Sanus Farmaceutica Ltda.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biolab Sanus Farmaceutica Ltda. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biolab Sanus Farmaceutica Ltda.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biolab Sanus Farmaceutica Ltda. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Biolab Sanus Farmaceutica Ltda. Snapshot
    • Biolab Sanus Farmaceutica Ltda. Overview
    • Key Information
    • Key Facts
  • Biolab Sanus Farmaceutica Ltda.- Research and Development Overview
    • Key Therapeutic Areas
  • Biolab Sanus Farmaceutica Ltda.- Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products- Monotherapy
  • Biolab Sanus Farmaceutica Ltda.- Pipeline Products Glance
    • Biolab Sanus Farmaceutica Ltda.- Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Biolab Sanus Farmaceutica Ltda.- Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Biolab Sanus Farmaceutica Ltda.- Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Biolab Sanus Farmaceutica Ltda.- Drug Profiles
    • BL-123
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BL-125
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-5109
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BL-122
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BL-214
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BL-249
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Biolab Sanus Farmaceutica Ltda.- Pipeline Analysis
    • Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Target
    • Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Route of Administration
    • Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Molecule Type
    • Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Mechanism of Action
  • Biolab Sanus Farmaceutica Ltda.- Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Biolab Sanus Farmaceutica Ltda., Key Information
  • Biolab Sanus Farmaceutica Ltda., Key Facts
  • Biolab Sanus Farmaceutica Ltda.- Pipeline by Indication, 2014
  • Biolab Sanus Farmaceutica Ltda.- Pipeline by Stage of Development, 2014
  • Biolab Sanus Farmaceutica Ltda.- Monotherapy Products in Pipeline, 2014
  • Biolab Sanus Farmaceutica Ltda.- Phase III, 2014
  • Biolab Sanus Farmaceutica Ltda.- Phase I, 2014
  • Biolab Sanus Farmaceutica Ltda.- Preclinical, 2014
  • Biolab Sanus Farmaceutica Ltda. -Pipeline by Target, 2014
  • Biolab Sanus Farmaceutica Ltda.- Pipeline by Route of Administration, 2014
  • Biolab Sanus Farmaceutica Ltda.- Pipeline by Molecule Type, 2014
  • Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Mechanism of Action, 2014
  • Biolab Sanus Farmaceutica Ltda., Other Locations

List of Figures

  • Biolab Sanus Farmaceutica Ltda. - Pipeline by Top 10 Indication, 2014
  • Biolab Sanus Farmaceutica Ltda. - Pipeline by Stage of Development, 2014
  • Biolab Sanus Farmaceutica Ltda. - Monotherapy Products in Pipeline, 2014
  • Biolab Sanus Farmaceutica Ltda. - Pipeline by Top 10 Molecule Type, 2014
Back to Top